Neurogene Inc. Files 8-K with SEC

Ticker: NGNE · Form: 8-K · Filed: Oct 9, 2025 · CIK: 1404644

Sentiment: neutral

Topics: disclosure, financials

TL;DR

Neurogene Inc. filed an 8-K on 10/9/25. Standard disclosure update.

AI Summary

Neurogene Inc. filed an 8-K on October 9, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as Neoleukin Therapeutics, Inc., is based in New York, NY, and operates in the pharmaceutical preparations industry.

Why It Matters

This filing provides an update on Neurogene Inc.'s regulatory disclosures and financial status, which is crucial for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for disclosure purposes and does not appear to contain any significant new risks or material adverse events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Neurogene Inc.?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on October 9, 2025.

What was Neurogene Inc.'s former name?

Neurogene Inc.'s former name was Neoleukin Therapeutics, Inc.

In which state was Neurogene Inc. incorporated?

Neurogene Inc. was incorporated in Delaware.

What is the business address of Neurogene Inc.?

The business address of Neurogene Inc. is 535 W 24th Street, 5th Floor, New York, NY 10011.

Filing Stats: 647 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2025-10-09 07:01:21

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On October 9, 2025, Neurogene Inc. (the "Company") issued a press release announcing the completion of discussions with the U.S. Food and Drug Administration ("FDA") on the protocol for its anticipated registrational trial and the Company's plans to dose a first participant in that registrational trial in the fourth quarter of 2025, as well as information from a presentation on preclinical data that provides further evidence that intracerebroventricular (ICV) administration is superior to intrathecal lumbar (IT-L) in reaching key brain regions underlying Rett syndrome. The preclinical data is being presented as a poster at the European Society of Gene & Cell Therapy (ESGCT) Annual Congress in Seville, Spain. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on October 9, 2025, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated October 9, 2025 99.2 Corporate Presentation (October 9, 2025) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: October 9, 2025 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing